Ascendis Pharma Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 16, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	12,180	11,564	7,208	6,233	5,978	6,447
Market Cap Growth	-	60.42%	15.65%	4.26%	-7.28%	-17.80%
Enterprise Value	12,436	11,826	7,479	6,469	5,765	5,873
PS Ratio	16.91	15.64	21.77	24.16	124.47	833.13
PB Ratio	-74.81	-69.18	-74.90	-44.23	24.19	7.33
P/TBV Ratio	26.63	-	-	-	26.49	8.39
P/FCF Ratio	268.22	209.00	-	-	-	-
P/OCF Ratio	225.99	209.00	-	-	-	-
EV/Sales Ratio	17.24	16.00	22.59	25.08	120.03	758.93
EV/FCF Ratio	273.86	213.74	-	-	-	-
Debt / Equity Ratio	0.79	-2.37	-3.45	-1.53	1.83	0.11
Debt / FCF Ratio	14.82	16.18	-	-	-	-
Net Debt / Equity Ratio	0.66	-1.57	-2.81	-1.68	-0.86	-0.65
Net Debt / EBITDA Ratio	-107.02	-2.16	-1.14	-0.56	0.42	1.32
Net Debt / FCF Ratio	5.35	4.75	-0.97	-0.52	0.46	1.31
Asset Turnover	0.52	0.58	0.36	0.28	0.05	0.01
Inventory Turnover	0.10	-0.32	-0.18	0.26	-0.12	-0.09
Quick Ratio	0.68	0.72	0.81	0.62	4.44	7.03
Current Ratio	1.00	1.04	1.17	0.95	5.39	8.03
Return on Equity (ROE)	305.05%	169.84%	300.78%	-818.43%	-101.69%	-44.54%
Return on Assets (ROA)	1.30%	-11.77%	-28.17%	-48.30%	-52.15%	-43.72%
Return on Invested Capital (ROIC)	4.11%	-57.89%	-156.57%	-738.04%	-330.83%	-174.13%
Return on Capital Employed (ROCE)	-1.31%	-53.99%	-154.56%	-90.43%	-59.04%	-47.27%
FCF Yield	0.37%	0.48%	-	-	-	-
Buyback Yield / Dilution	-4.69%	-4.69%	-2.85%	-0.38%	-2.37%	-8.21%
Total Shareholder Return	-4.69%	-4.69%	-2.85%	-0.38%	-2.37%	-8.21%